• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Cipla gets USFDA approvals for two drugs

      Posted AtMyiris.com

      Cipla, one of India`s largest pharmaceutical companies has received approvals for two drugs namely Stavudine and Levetiracetam from the United States Food and Drug Administration (USFDA).

      While Stavudine will be available in solution form in the strengths of 1 mg/ml, Levetiracetam could be tablet in the strengths of 250 mg, 500 mg 750 mg respectively.

      Stavudine is used for use in combination with other antiretroviral agents for the treatment of HIV infection in adults and children. Levetiracetam tablets are indicated as adjunctive therapy in treatment of myoclonic Seizures in adults and adolescents from 12 years of age with juvenile myoclonic Epilepsy.

      April 01, 2009


      Share this Article!

    Back to top^